SANOFI overview

Dupixent ® (dupilumab) s ignificantly i mproved i tch and h ives in p atients with c hronic s pontaneous u rticaria, a s tep f orward in d emonstrating the r ole of t ype 2 i nflammation in t hese p atients Fifth disease that Dupixent has demonstrated positive pivotal results Phase 3 trial met its primary endpoints and all key secondary endpoints at 24 weeks, showing Dupixent nearly doubled reduction in itch and urticaria activity scores CSU results further demonstrate the potential of...

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French s ociété anonyme with a registered share capital of 2,517,943,476 € Registered office : 54, rue La Boétie - 75008 Paris - France Registered at the Paris Commercial and Companies...

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French s ociété anonyme with a registered share capital of 2,517,943,476 € Registered office : 54, rue La Boétie - 75008 Paris - France Registered at the Paris Commercial and Companies...

Availability of the Q 2 202 1 Memorandum for modelling purposes Paris, France – June 2 5 , 20 20 - Sanofi announced today that its Q2 2021 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q2-results-2021 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on...

Libtayo ® ( cemiplimab ) a pproved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor Libtayo now approved by the European Commission for three advanced cancers P ARIS and T ARRYTOWN , NY – Ju ne 25 , 20 21 – The European Commission (EC) has approved Sanofi and Regeneron’s PD-1...

European Commission approves Aubagio ® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis PARIS – June 18 , 20 21 - The European Commission (EC) has approved Aubagio ® (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS). The EC approval is based on data from the Phase 3 TERIKIDS study. The approval confirms Aubagio as...

New p ivotal data at EHA 2021 reinforces s utimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in p eople with cold agglutinin disease , a serious and chronic autoimmune hemolytic anemia Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningful Findings provide further evidence that sutimlimab results in rapid inhibition of...

Sanofi partner ing with leading academic cooperative groups to study a mcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer Sanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and Alliance Foundation Trials (AFT), which are world-leading academic groups delivering practice-changing breast cancer clinical research Collaborating on the Phase 3 AMEERA-6 study expected to be the...

Sanofi provides update on venglustat clinical program P ARIS – JUNE 1 , 20 21 – A pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease (ADPKD) did not meet futility criteria, and the company has halted the clinical program in ADPKD. The safety profile of venglustat remains consistent with previously reported results with more than 500 patients treated to date over a period of up to four years across all clinical programs. Biomarker data from the study...

Sanofi and GSK initiate global Phase 3 clin i cal efficacy study of COVID-19 vaccine candidate Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants A booster study program will begin in the coming weeks to complement Phase 3 trial Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021 PARIS and LONDON – May 27, 2021 – Today, Sanofi...

Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting Early clinical data for investigational oral selective estrogen receptor (SERD), amcenestrant, show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancer Data that reinforce Libtayo ® (cemiplimab-rwlc) as a standard of care in advanced non-melanoma skin cancer and advanced non-small cell lung cancer, including new data in historically underrepresented patients with brain metastases...

Sanofi establishes three -year collaboration with Stanford Medicine to accelerate immunology research Projects led by collaborating researchers from the two organizations will focus on autoimmune diseases and inflammatory conditions PARIS and Palo Alto, CA – May 6, 202 1 – Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the two organizations and their scientists will work to advance the understanding of immunology and...

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French société anonyme with a registered share capital of 2,517,943,476 € Registered office : 54, rue La Boétie - 75008 Paris - France Registered at the Paris Commercial and Companies...

Annual General Meeting of April 30 , 202 1 Approval of the financial statements for the fiscal year 2020 Dividend of €3.20 per share payable as of May 7, 2021 Board composition: renewals, ratification of a co-opting Director and appointment of one new Director Paris, France – April 30 , 202 1 – The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2021, without the physical presence of its shareholders, in accordance with the derogating measures adapting the rules...

Paris, April 28, 2021 Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% at CER driven by growth drivers Dupixent ® and Vaccines Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6% to €1,047 million) and oncology launches Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere General Medicines core assets grew 4.4%, while GBU sales were down 3.8% CHC...